Zydus receives FDA’s ODD for Desidustat for the treatment of beta-thalassemia
Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
Budesonide is indicated for mild to moderate active Crohn's disease involving the ileum and/or the ascending colon in adults and children 8 years of age and olde
With over two decades of extensive experience, Lal has established himself as a transformational leader in the FMCG and consumer goods sectors
Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis
Liothyronine tablets will be manufactured at Zydus' plant in Ahmedabad SEZ
Deflazacort oral suspension is indicated for treating Duchenne Muscular Dystrophy in patients 5 years of age and older
Zydus Pinkathon will be led by women to raise awareness on breast cancer and women's health
The facility has been classified as Voluntary Action Indicated
He has been associated with the Zydus Group since 2009
Zydus will work closely with the USFDA to address and resolve the observations in an expeditious manner
Subscribe To Our Newsletter & Stay Updated